No Data
BAIYUNSHAN PH (600332.SH): Subsidiary received the pharmaceutical registration certificate from Macau.
On January 9, Gelonghui announced that BAIYUNSHAN PH (600332.SH) reported that its holding subsidiary, Guangzhou BAIYUNSHAN Guanghua Pharmaceutical Co., Ltd., received the "Chinese Patent Medicine Registration Certificate" issued by the Macao Special Administrative Region's Drug Administration, with the product names: Xiao Chai Hu Granules (sugar-free type) [BAIYUNSHAN], Xiao Chai Hu Granules [BAIYUNSHAN]. The functions and indications of Xiao Chai Hu Granules are to release the exterior, disperse heat, and soothe the liver and stomach. It is used for external contraction diseases, with pathogenic factors invading the Shaoyang syndrome, symptoms include alternating chills and fever, fullness in the chest and hypochondria, loss of appetite, irritability with a tendency to vomit, and bitter taste in the mouth with dryness in the throat.
BAIYUNSHAN PH (600332.SH): The BYS30 particles have received the drug clinical trial approval notification.
On January 9, Gelonghui reported that BAIYUNSHAN PH (600332.SH) announced that its subsidiary, Guangzhou BAIYUNSHAN Pharmaceutical Group Co., Ltd., received the "Clinical Trial Approval Notification" issued by the National Medical Products Administration for the drug named: BYS30 Granules. BYS30 Granules is a Class 1 innovative Traditional Chinese Medicine compound formulation developed by the BAIYUNSHAN Pharmaceutical Factory, indicated for knee osteoarthritis.
BAIYUNSHAN PH (600332.SH): LBZ-18 and LBZ-18 oral emulsion have received the clinical trial approval notice.
On January 9, Gelonghui reported that BAIYUNSHAN PH (600332.SH) announced that its subsidiary, Guangzhou BAIYUNSHAN Hanfang Modern Pharmaceutical Co., Ltd., received the "Notice of Approval for Clinical Trial of Drugs" issued by the National Medical Products Administration, with the drug names: LBZ-18 and LBZ-18 Oral Emulsion. LBZ-18 Oral Emulsion is an Innovative Drug of Category I Traditional Chinese Medicine independently developed by BAIYUNSHAN Hanfang, indicated for invigorating qi and strengthening the spleen, used for the treatment of cancer-related fatigue in tumor patients.
The construction of specialized traditional Chinese medicine departments is accelerating, and TCM clinical services maintain high prosperity.
Golden Owl Financial News | According to recent reports from CCTV News on the National Administration of Traditional Chinese Medicine, through a series of measures such as accelerating the construction of Traditional Chinese Medicine advantageous specialties, the high-quality development of county-level Traditional Chinese Medicine Hospitals, and the construction of collaborative hospitals for Chinese and Western medicine, China has now established 1,158 national advantageous specialties in Traditional Chinese Medicine. The next step will be to build a network of advantageous specialties in Traditional Chinese Medicine and create clusters of advantageous specialties, focusing on strengthening the construction of pediatrics, geriatrics, and mental illness specialties, as well as promoting the foundation and quality of county-level Traditional Chinese Medicine hospitals and enhancing grassroots Traditional Chinese Medicine service capabilities. Under the dual drive of policy and clinical demand, the Traditional
GTJA: The centralized procurement of Chinese Patent Medicine is still in the early stages, and quality improvement and expansion are expected to continue to progress.
GTJA released a Research Report stating that the bidding for the third batch of national Chinese Patent Medicine centralized procurement has opened, with the reduction slightly exceeding expectations.
Baiyunshan Pharma's Venture Capital Fund Completes Registration
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
No Data
